Clinical Trial Update: Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating bitopertin, a selective GlyT1 inhibitor, for steroid-refractory Diamond-Blackfan Anemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diamond-blackfan Anemia

Drugs mentioned

• Bitopertin (bitopertin)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Steroid-refractory Diamond-Blackfan Anemia (DBA) | Phase 1, Phase 2 | Status: COMPLETED